Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


Biogen Investigational Drug Shows Early Promise


 
Photo from the Sept. 1 issue of Nature courtesy of Biogen and the study authors.

Boston-based biotech company Biogen had pre-clinical research and Phase 1b results for aducanumab, its investigational antibody treatment for early Alzheimer's disease, published in the Sept. 1, 2016 issue of Nature.

Information released by Biogen said the pre-clinical animal model and Phase 1b placebo-controlled study in prodromal and mild AD patients (n=165), both demonstrated aducanumab reduced amyloid-beta in the brain and that the reduction was dose-dependent. With the association of amyloid plaque and AD, the hypothesis is that removing the plaque could slow the clinical decline in AD patients. Exploratory results from the Phase 1b study demonstrated dose- and time-dependent slowing of clinical decline as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB) and the Mini-Mental State Examination (MMSE) scores.

"These early studies of aducanumab show its effectiveness in removing amyloid plaque from the brain, as well as its potential effect on the slowing of cognitive decline in patients suffering from Alzheimer's disease," said Alfred Sandrock, MD, PhD, executive vice president and chief medical officer at Biogen.

Aducanumab is a human recombinant monoclonal antibody (mAb) derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune's technology platform called Reverse Translational Medicine (RTM). Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.

In the Phase 1b study, aducanumab demonstrated acceptable safety and tolerability profiles. The most frequently reported treatment-related serious adverse event and adverse event was ARIA (amyloid-related imaging abnormalities). Two larger Phase 3 trials are currently underway.

 
Share:

Related Articles:


Recent Articles

Nashville's First Dedicated Clinic for Rape Exams Begins Taking Clients

Website includes interactive tool to help sexual assault victims determine if the SAFE Clinic is right for them

Read More

Practicing with Precision

Precision medicine holds great promise to tailor treatment in a manner that maximizes outcomes, yet a number of barriers exist that hinder the rapidly growing discipline's integration into daily practice.

Read More

Physician Spotlight: Brandon Downs, MD

Dr. Brandon Downs of Orthopaedic Specialists offers convenient, comprehensive services to patients who rely on his expertise in minimally invasive joint replacement and sports medicine.

Read More

Vanderbilt Bone & Joint Franklin Expands Staff, Adds Pediatric Services

Vanderbilt Bone & Joint Franklin greatly expands staff and adds pediatric services.

Read More

Regenerative Medicine in Orthopaedics

Regenerative medicine means less pain, more options for orthopaedic patients.

Read More

SJRI Opens Dickson Clinic

Southern Joint Replacement Institute opens Dickson clinic.

Read More

Health:Further Keynote Speakers Offer Energy And Insight

Although the annual Health:Further conference is best known for bringing innovative start-ups and investors together, the event also attracts healthcare and business organizations that have massive scale.

Read More

Industry Leaders Announce Innovative Orthopaedic Partnership

Saint Thomas Health, BlueCross BlueShield of Tennessee and Tennessee Orthopaedic Alliance recently announced a collaborative partnership for joint replacement.

Read More

Fighting the Good Fight

Franklin company mitigating cybersecurity risks for healthcare organizations nationwide.

Read More

Fighting the Good Fight

Franklin company mitigating cybersecurity risks for healthcare organizations nationwide.

Read More

Email Print
 
 

 

 


Tags:
Aducanumab, Alfred Sandrock, Alzheimer's, Alzheimer's Disease Neuroimaging Initiative, Amyloid Plaque, Biogen, Cognitive Decline
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: